Biotech News Today
Latest headline on this page:
1 headline on Biotech appeared in our news feed in the last 7 days without a measured price move.
What moved — last 7 days
| Time | Ticker | Headline | 1 min | Reaction |
|---|---|---|---|---|
| Oct 19, 07:00:17 ET | BMY | At the ESMO conference, Bristol‑Myers Squibb (BMY) is set to present oncology data. | — | No measured move |
Moves are measured against the price two minutes before each headline crossed, using validated 1-minute bars captured at publish time. A dash means no bar was available for that window. Reaction pending means the measuring window for that headline is still open. Not attributed means the headline does not name the company the move was measured on, so we hold the number back. Times are New York ET. Headlines appear here 1 minute after they cross the live tape.
Our analysis
Roche Pays Hansoh $400 Million Upfront in an ADC Deal Worth More Than $15 Billion
Hansoh disclosed the deal on October 19, 2026, while Hong Kong was closed for a holiday. Its upfront payment is more than twice the largest Hansoh …
Merck KGaA to Buy Silence Therapeutics (SLN) for $20 a Share: Why the Stock More Than Doubled
Monday, Oct 19, 2026 · Merck KGaA of Germany is paying $20.00 per ADS in cash, about $1.3 billion, for the maker of the blood-cancer drug divesiran.
ADC Therapeutics (ADCT) stock jumps 12.78% on an $86.6 million PIPE and a debt reset, October 8, 2026
Thursday, Oct 8, 2026 · The new equity mostly prepays the Blue Owl loan, while HealthCare Royalty drops the $150 million it was owed on a sale. The stock rose 12.78% …
argenx (ARGX) stock falls after the Phase 3 UNITY trial of Vyvgart in Sjögren's disease is stopped for futility, October 8, 2026
Thursday, Oct 8, 2026 · An interim analysis found UNITY could not meet its primary endpoint. The shares were down 15.7% in Brussels by mid-morning, though analysts had given the trial …
Halozyme wins Dutch ruling against Merck's subcutaneous Keytruda: the eight markets where Keytruda SC is now blocked
Wednesday, Oct 7, 2026 · The Hague found Merck's under-the-skin Keytruda infringes Halozyme's EP 2,797,622 patent, upheld the patent and barred the product in eight markets. Intravenous Keytruda is unaffected.
Vaxcyte's $1 billion stock, warrant and convertible note offering: why PCVX fell 8.06% after Phase 3 data
Tuesday, Oct 6, 2026 · Vaxcyte priced $500 million of stock at $64.00 and $500 million of 1.50% notes convertible at about $89.60 after positive Phase 3 data; PCVX fell 8.06% …
Caribou Biosciences (CRBU) ends its CAR-T programs: the cash left for a strategic review
Tuesday, Oct 6, 2026 · Caribou stopped both of its CAR-T programs and opened a strategic review. CRBU already traded below its June 30 cash per share before the news.
Why Connect Biopharma stock sank on its asthma data and rallied on its COPD data
Wednesday, Sep 30, 2026 · Both rademikibart readouts were announced as positive. The asthma study missed its primary endpoint and the COPD study met it, and pre-market trading priced that difference …
Why Was Contineum Therapeutics Stock Down on Sep 14, 2026?
Monday, Sep 14, 2026 · The J&J-partnered Phase 2 MOONLIGHT-1 trial of JNJ-5120 (PIPE-307) in depression missed its primary endpoint. Contineum traded at $14.00 ten minutes into after-hours trading, 5.533% below …
Why Was Tenaya Therapeutics Stock Up on Sep 14, 2026?
Monday, Sep 14, 2026 · The FDA granted RMAT designation to Tenaya's TN-401 gene therapy for PKP2-associated ARVC. The stock was up 8.91% on the session at 12:29 ET.
Why Was Perspective Therapeutics Stock Up on Sep 14, 2026?
Monday, Sep 14, 2026 · Perspective signed a supply agreement with Merck to test [212Pb]PSV359 with Keytruda in FAP-α positive tumors. The stock was up 2.31% on the session at 12:26 …
Why Was Nasus Pharma Stock Up on Sep 14, 2026?
Monday, Sep 14, 2026 · The FDA cleared Nasus Pharma's IND for NS002, its nasal epinephrine powder for anaphylaxis, ahead of a pivotal study planned for the fourth quarter of 2026. …
Why Was Tyra Biosciences Stock Up on Sep 14, 2026?
Monday, Sep 14, 2026 · Tyra priced a $400.0 million stock and pre-funded warrant offering at $22.03 five days after its SURF302 bladder cancer data. The shares were up 15.66% on …
Why Was Corbus Pharmaceuticals Stock Up on Sep 14, 2026?
Monday, Sep 14, 2026 · Corbus reported 5.0% placebo-adjusted weight loss at 12 weeks for oral CRB-913 at 60 mg in CANYON-1. The stock swung between $9.91 and $5.56 in the …
Why Was Imunon Stock Moving on Sep 10, 2026?
Thursday, Sep 10, 2026 · Imunon signed a Cooperative Research and Development Agreement with the National Cancer Institute for its IL-12 immunotherapy IMNN-001. The stock jumped 4.878% in the first minute …
Why Was Ultragenyx (RARE) Stock Down on Sep 2, 2026?
Wednesday, Sep 2, 2026 · The Aspire trial of GTX-102 missed both its endpoints — and the measured crater took 43.65% out in fifteen minutes.
Can-Fite (CANF) Surged 38% on Survival Data That Proves Nothing Yet — Measured
Wednesday, Sep 2, 2026 · The data is pooled and blinded — the company says no efficacy conclusion can be drawn. The measured +37.81% bought a sooner answer, not an answer.
Why Was Pluri Stock Up on Aug 27, 2026?
Thursday, Aug 27, 2026 · PLUR rose on an equity offering because the $1.50 deal price stood above the pre-event market, though measured volume was thin.
Why Was Kazia Therapeutics Stock Down on Aug 27, 2026?
Thursday, Aug 27, 2026 · Kazia's initial offering announcement removed pricing certainty; the next-day terms separated $40 million of upfront proceeds from contingent warrants.
Why Was Celularity Stock Up on Aug 27, 2026?
Thursday, Aug 27, 2026 · Celularity's manufacturing collaboration produced a two-stage repricing, while the headline purchase opportunity remains conditional and multi-year.
Why Was Quoin Pharmaceuticals Stock Up on Aug 28, 2026?
Friday, Aug 28, 2026 · QNRX rose after Quoin paired encouraging early QRX003 data with financing designed to extend its development runway.
Why Was Eli Lilly Stock Up on Aug 19, 2026?
Wednesday, Aug 19, 2026 · Lilly rose 4.46% and announced nothing. Every major drug name rose with it while the S&P 500 barely moved — and Lilly's own earnings beat measured …
Why Was Merck Stock Up on Aug 19, 2026?
Wednesday, Aug 19, 2026 · A trial where Merck's own blockbuster was the comparator just beat it — and Merck co-owns the regimen that did.
Moderna Has 9 Trials Riding on the Method That Just Worked
Wednesday, Aug 19, 2026 · One adjuvant melanoma readout does not reprice a company. A 9-trial programme testing the same procedure in other cancers does.
The FDA Just Approved the First Cancer Virus Therapy Paired With a Checkpoint Inhibitor — and Replimune Made It
Sunday, Aug 9, 2026 · The FDA granted accelerated approval to Replimune's oncolytic virus therapy, TUDRIQEV, in combination with the checkpoint inhibitor nivolumab, for adults with advanced melanoma that progressed on …
Why Was Replimune (REPL) Stock Moving on Aug 9, 2026?
Sunday, Aug 9, 2026 · Replimune is a clinical-stage biotech developing oncolytic virus therapies for cancer. This page tracks what's actually moving the stock — FDA decisions, analyst calls, and trial …
Why Was Ensysce Biosciences Stock Up on Aug 6, 2026?
Thursday, Aug 6, 2026 · Ensysce Biosciences is trading sharply higher today, extending its initial reaction to this morning's announcement that it completed the acquisition of Cy Biopharma alongside financing lined …
Ensysce Biosciences Bought a Pain-Drug Startup and Lined Up as Much as $77.2 Million to Fund It Through 2028
Thursday, Aug 6, 2026 · Ensysce Biosciences, a clinical-stage biotech, completed its acquisition of Cy Biopharma on August 6, 2026, alongside $17.1 million in cash financing and a $21.5 million Series …
Why Was Vanda Pharmaceuticals (VNDA) Stock Up on Aug 24, 2026?
Monday, Aug 24, 2026 · The European Commission made it formal: the first orphan designation ever granted for generalized pustular psoriasis — five weeks after the committee opinion the wires blurred …
Why Was Travere Therapeutics Stock Up on Aug 5, 2026?
Wednesday, Aug 5, 2026 · FILSPARI sales nearly doubled year over year, with new-patient volume still accelerating — a genuine demand story, not a cost-cut beat.
BioNTech Q2 2026: A 60% Revenue Collapse the Stock Didn't React To
Tuesday, Aug 4, 2026 · BioNTech reported second-quarter 2026 results on August 4, 2026.
Why Was BioNTech Stock Barely Moving on Aug 4, 2026?
Tuesday, Aug 4, 2026 · BioNTech's revenue fell roughly 60% and guidance was cut — but the stock didn't budge, because the market stopped valuing it on COVID vaccine sales a …
Moderna Q2 2026: Revenue Beat Overshadowed by Norovirus Trial Miss
Saturday, Aug 1, 2026 · Moderna reported second-quarter 2026 results before the market opened on July 31, 2026.
Why Was Moderna Stock Up on Sep 14, 2026?
Monday, Sep 14, 2026 · Moderna kept its 2028 break-even target and 2026 growth guidance at the Morgan Stanley healthcare conference. The stock rose 1.101% in ten minutes on below-normal volume.